Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index; 89 of the 278 sources its claims cite were checked for support.

Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications

Open access
Cosci, Fiammetta, Chouinard, Guy · 2020 · Psychotherapy and Psychosomatics

Abstract

Studies on psychotropic medications decrease, discontinuation, or switch have uncovered withdrawal syndromes. The present overview aimed at analyzing the literature to illustrate withdrawal after decrease, discontinuation, or switch of psychotropic medications based on the drug class (i.e., benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, antidepressants, ketamine, antipsychotics, lithium, mood stabilizers) according to the diagnostic criteria of Chouinard and Chouinard [Psychother Psychosom. 2015;84(2):63-71], which encompass new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. All these drugs may induce withdrawal syndromes and rebound upon discontinuation, even with slow tapering. However, only selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, and antipsychotics were consistently also associated with persistent post-withdrawal disorders and potential high severity of symptoms, including alterations of clinical course, whereas the distress associated with benzodiazepines discontinuation appears to be short-lived. As a result, the common belief that benzodiazepines should be substituted by medications that cause less dependence such as antidepressants and antipsychotics runs counter the available literature. Ketamine, and probably its derivatives, may be classified as at high risk for dependence and addiction. Because of the lag phase that has taken place between the introduction of a drug into the market and the description of withdrawal symptoms, caution is needed with the use of newer antidepressants and antipsychotics. Within medication classes, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, and quetiapine are more likely to induce withdrawal. The likelihood of withdrawal manifestations that may be severe and persistent should thus be taken into account in clinical practice and also in children and adolescents.

Overview

CoChat Summary

TL;DR

This overview applies Chouinard and Chouinard’s diagnostic criteria to withdrawal after decrease, discontinuation, or switch of psychotropic medications, distinguishing new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. It concludes that all reviewed drug classes may induce withdrawal and rebound even with slow tapering, but SSRIs, SNRIs, and antipsychotics are consistently associated with persistent post-withdrawal disorders and potentially high severity, whereas benzodiazepine discontinuation distress appears short-lived.

Key findings

  • Withdrawal reactions can occur after abrupt discontinuation or gradual tapering; prevalence was reported as 54% among adults with serious mental illness, and antidepressant withdrawal incidence ranged from 27 to 86% (weighted average 56%). New withdrawal symptoms peak at 36–96 h, last up to 6 weeks, and are usually reversible; rebound symptoms return original symptoms at greater intensity; persistent post-withdrawal disorders last >6 weeks and are potentially irreversible.
  • SSRIs, SNRIs, and antipsychotics were consistently associated with persistent post-withdrawal disorders and increased severity, including altered clinical course. Venlafaxine withdrawal rates ranged from 23 to 78%, and levomilnacipran from 9 to 10%. Antipsychotic supersensitivity psychosis prevalence was reported as 65% in a long-acting injectable risperidone study, 26.5% in a retrospective aripiprazole-switch study, and 72% in treatment-resistant schizophrenia patients treated with second-generation antipsychotics.
  • Benzodiazepine new withdrawal symptoms are generally mild, transient, and subside within 2–4 weeks; 75% of patients withdrawn after long-term benzodiazepine use developed new withdrawal symptoms regardless of rapid or slow elimination. Rebound anxiety occurred in 5 of 7 (71.4%) bromazepam-treated patients versus 2 of 7 (28.6%) diazepam-treated patients. Persistent post-withdrawal disorders after long-term benzodiazepine use are described, but the literature is “hardly existent.”
  • Ketamine and probably its derivatives may be classified as high risk for dependence and addiction; new withdrawal symptoms typically begin within 24 h, last approximately 3 days, and may persist for 2 weeks. Lithium withdrawal evidence is weak and ambiguous, and data on mood stabilizers are limited.

Methods

  • Overview/review of the literature; MEDLINE was searched from inception to January 2020, with manual searching of reference lists and relevant reviews. Search terms combined “discontinuation/withdrawal” with drug-class terms (benzodiazepine, Z-drug, antidepressant, ketamine/esketamine, antipsychotic/neuroleptic, lithium, mood stabilizer).
  • Eligible articles were English, peer-reviewed papers reporting data on adult subjects who decreased, discontinued, or switched psychotropic medications. Titles and abstracts were screened by 1 reviewer; potentially relevant full reports were independently assessed by 2 reviewers to consensus.
  • Withdrawal symptoms were categorized using a previously used antidepressant discontinuation categorization (general, cardiovascular, gastrointestinal, genitourinary, sensory-related, neuromuscular, sexual, and central nervous system symptoms) and classified according to Chouinard and Chouinard’s criteria for new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders.

Limitations

  • Stated: evidence for lithium withdrawal is weak and ambiguous; literature on persistent post-withdrawal disorders after long-term benzodiazepine use is hardly existent, and no studies were found on managing benzodiazepine persistent post-withdrawal disorders. No persistent post-withdrawal data are published for Z-drugs, and data are limited for newer antidepressants, carbamazepine, valproate, and lamotrigine; no rebound or persistent post-withdrawal data are available for mood stabilizers.
  • Stated: proposed management strategies for SSRI/SNRI withdrawal—including hyperbolically decreasing dose patterns, multistep dose reduction, and Fava and Belaise’s pharmacological/non-pharmacological strategies—need testing in randomized controlled trials. One group CBT trial found only 37% (n = 26) discontinued antidepressants and 28% (n = 20) discontinued without recurrence, though timing and sample vulnerability may have contributed.
  • Evident: this is a narrative overview rather than a systematic review or meta-analysis; no formal quality appraisal or risk-of-bias assessment is described, title/abstract screening was done by one reviewer, and conclusions often rely on case reports, online reports, and limited controlled data. The authors also note a lag phase between drug marketing and description of withdrawal symptoms, which limits certainty for newer agents.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1159/000506868

Cites

220 of 220 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

37 Valid · 35 Not valid · 86 Not checked · 19 Own results and interpretations

91 more claims · 25 with their cited sources checked

Create a free account to see all 177 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 31
  • It may state two separate claims as one. 56
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

23 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 219 references

Cited by

See all 265

Metadata

Authors
Cosci, F., & Chouinard, G.
Affiliations
  • Maastricht University (NL)
  • McGill University (CA)
Venue
Psychotherapy and Psychosomatics
Publisher
S. Karger AG
Published
2020
Volume
89
Issue
5
Pages
283-306
ISSN
  • 0033-3190 (ISSN-L)
  • 1423-0348
OpenAlex
W3014423675
Cited by
265
References
219
Citations by year
2026: 35 · 2025: 34 · 2024: 53 · 2023: 45 · 2022: 37 · 2021: 45 · 2020: 16
FWCI
4.68
Type
journal article
Language
en
Open access
Licence
Locations
  • Psychotherapy and Psychosomatics (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, other-oa)
  • Florence Research (University of Florence) (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, other-oa)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
drug discontinuation, benzodiazepines, antidepressants, ketamine, antipsychotic drugs, lithium, mood stabilizers, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, quetiapine, drug addiction, children and adolescents
MeSH terms
Mental Disorders, Humans, Psychotropic Drugs, Substance Withdrawal Syndrome, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. https://app.cochat.ai/papers/10.1159/000506868
The paper
Cosci, F., & Chouinard, G. (2020). Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000506868

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.